Breast Cancer Foundation NZ
SAND
Early Breast Cancer clinical trials for ER+
This study aims to reduce inflammation in post-menopausal women with breast cancer through the use of asprin.
Previous work suggests that the presence of inflammation in post-menopausal breast cancer is associated with a poor response to aromatase inhibitor treatment. Here, an anti-inflammatory drug aspirin is given with the aromatase inhibitor, and the breast cancer will be sampled before and after the treatment, given in the window of time between diagnosis and definitive surgery.
Key inclusion criteria
- ER positive, stage 1-2 breast cancer, post-menopausal, no prior therapy
- Minimum age: 50 Years
Key exclusion criteria
- not post-menopausal, prior breast cancer, other illnesses
New Zealand
If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz
Similar clinical trials
For Early Breast Cancer , Supportive Care
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz
Interested in a clinical trial?
Subscribe for updates & stay in the loop with new studies.